IP Library Granted Patent US 7,056,927
Granted Patent B2
US 7,056,927 · App. 10/885,491 · Granted Jun 6, 2006

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Assignee: Neurocrine Biosciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,056,927
App. No.
10/885,491
Granted
Jun 6, 2006
Kind
B2
Abstract

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R 1a , R 1b , R 1c , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Claims (60)

1. A compound having the following structure:

or a stereoisomer or pharmaceutically acceptable salt thereof,

wherein:

R 1a , R 1b and R 1c are the same or different and independently hydrogen, halogen, C 1-4 alkyl, hydroxy or alkoxy, or R 1a and R 1b taken together form —OCH 2 O— or —OCH 2 CH 2 —;

R 2a and R 2b are the same or different and independently hydrogen, halogen, trifluoromethyl, cyano or —SO 2 CH 3 ;

R 3 is hydrogen or methyl;

R 4 is phenyl or C 3-7 alkyl;

R 5 is hydrogen or C 1-4 alkyl;

R 6 is —COOH or an acid isostere; and

X is C 1-6 alkanediyl optionally substituted with from 1 to 3 C 1-6 alkyl groups.

2. The compound of claim 1 wherein R 1a is halogen.

3. The compound of claim 1 wherein R 1b is alkoxy.

4. The compound of claim 3 wherein R 1b is methoxy.

5. The compound of claim 1 wherein R 1c is halogen.

6. The compound of claim 5 wherein R 1c is fluoro or chloro.

7. The compound of claim 1 wherein R 2a is halogen.

8. The compound of claim 1 wherein R 2b is hydrogen, halogen or —SO 2 CH 3 .

9. The compound of claim 1 wherein R 3 is hydrogen.

10. The compound of claim 1 wherein R 3 is methyl.

11. The compound of claim 1 wherein R 4 is phenyl.

12. The compound of claim 1 wherein R 4 is C 3-7 alkyl.

13. The compound of claim 12 wherein C 3-7 alkyl is cyclopentyl or cyclohexyl.

14. The compound of claim 1 wherein R 5 is H or methyl.

15. The compound of claim 1 wherein R 6 is —COOH.

16. The compound of claim 1 wherein R 6 is an acid isostere.

17. The compound of claim 16 wherein the acid isostere is tetrazol-5-yl.

18. The compound of claim 1 wherein X is a straight chain C 1-6 alkanediyl.

19. The compound of claim 18 wherein the straight chain C 1-6 alkanediyl is —CH 2 CH 2 CH 2 —.

20. The compound of claim 19 wherein R 4 is phenyl.

21. The compound of claim 20 wherein R 1a and R 2a are halogen.

22. The compound of claim 21 wherein R 3 is methyl.

23. The compound of claim 21 wherein R 3 is hydrogen.

24. The compound of claim 1 wherein X is a branched C 1-6 alkanediyl.

25. The compound of claim 1 wherein the compound is 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione, 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(3-isopropylphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione, 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-(cyclohexyl)ethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione, or 3-[2(R)-{2-[1-(5-tetrazoyl)propyl]-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-methylsulfonylbenzyl]-6-methylpyrimidine-2,4(1H,3H)-dione.

26. The compound of claim 1 wherein the compound is 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chlorophenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-pyrimidine-2,4(1H,3H)-dione, 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-pyrimidine-2,4(1H,3H)-dione, 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methylphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-pyrimidine-2,4(1H,3H)-dione, 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chlorophenyl)-1-[2-fluoro-6-(methylsulfonyl)benzyl]-pyrimidine-2,4(1H,3H)-dione, 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-pyrimidine-2,4(1H,3H)-dione, or 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-(isobutyl)ethyl]-5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-pyrimidine-2,4(1H,3H)-dione.

27. The compound of claim 15 , wherein R 1a is halogen and R 1b is alkoxy.

28. The compound of claim 27 , wherein R 2a is halogen and R 2b is halogen or trifluoromethyl.

29. The compound of claim 28 , wherein R 3 is methyl.

30. The compound of claim 15 , wherein X is a straight chain C 1-6 alkanediyl.

31. The compound of claim 30 , wherein R 4 is phenyl, cyclohexyl or cyclopentyl.

32. The compound of claim 31 , wherein R 5 is hydrogen or methyl.

33. The compound of claim 15 , wherein:

R 1a is halogen;

R 1b is alkoxy;

R 2a is halogen;

R 2b is halogen or trifluoromethyl;

R 3 is methyl; and

X is a straight chain C 1-6 alkanediyl.

34. The compound of claim 33 , wherein R 4 is phenyl, cyclohexyl or cyclopentyl, and R 5 is hydrogen or methyl.

35. The compound of claim 34 , wherein R 1a is fluoro and R 1b is methoxy.

36. The compound of claim 35 , wherein R 2a is fluoro and R 2b is trifluoromethyl.

37. The compound of claim 36 , wherein X is —(CH 2 CH 2 CH 2 )—.

38. The compound of claim 37 , wherein R 4 is phenyl.

39. The compound of claim 38 , wherein R 5 is hydrogen.

40. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

41. A pharmaceutical composition comprising a compound of claim 15 and a pharmaceutically acceptable carrier or diluent.

42. A pharmaceutical composition comprising a compound of claim 25 and a pharmaceutically acceptable carrier or diluent.

43. A pharmaceutical composition comprising a compound of claim 33 and a pharmaceutically acceptable carrier or diluent.

44. A pharmaceutical composition comprising a compound of claim 37 and a pharmaceutically acceptable carrier or diluent.

45. A pharmaceutical composition comprising a compound of claim 39 and a pharmaceutically acceptable carrier or diluent.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 16, 2008
From: NEUROCRINE BIOSCIENCES, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021984/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2004
From: GUO, ZHIQIANG; CHEN, YONGSHENG; WU, DONGPEI; CHEN, CHEN; WADE, WARREN; DWIGHT, WESLEY J.; HUANG, CHARLES Q.; TUCCI, FABIO C.
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 015272/0581 →
Continuity (2)
Provisional Application 6048543400 · Jul 7, 2003
Related Publication 20050038057A1 · Feb 17, 2005